Tratamiento Dirigido en el Cáncer de Pulmón Microcítico: El Papel de los Marcadores
|
Tratamiento Dirigido en el Cáncer de Pulmón Microcítico: El Papel de los Marcadores |
1 |
|
Introduction |
2 |
|
Número de diapositiva 3 |
3 |
|
Número de diapositiva 4 |
4 |
|
NSCLC vs. SCLC – drivers vs. tumor suppressors |
5 |
|
Comprehensive Genomic Profile of SCLC |
6 |
|
Número de diapositiva 7 |
7 |
|
Número de diapositiva 8 |
8 |
|
Mutational Load |
9 |
|
Número de diapositiva 10 |
10 |
|
Número de diapositiva 11 |
11 |
|
DLL3 is a dominant inhibitor of Notch signaling |
12 |
|
Rovalpituzumab Tesirine (Rova-T)A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate |
13 |
|
Número de diapositiva 14 |
14 |
|
SCRX16-001: First-in-Human Study Schema |
15 |
|
Subject Baseline Characteristics (n=74) |
16 |
|
Central Review Validates Confirmed Responses |
17 |
|
Confirmed Responses Comparable in 2nd & 3rd Line |
18 |
|
Favorable Comparison vs. Existing 2L and 3L CTX |
19 |
|
Best Responses per Investigator by DLL3 |
20 |
|
SCLC Kaplan-Meier Overall Survival |
21 |
|
Adverse Event Profile in SCLC Subjects (n=74) |
22 |
|
Número de diapositiva 23 |
23 |
|
Número de diapositiva 24 |
24 |
|
RovA-TOngoing Studies in SCLC |
25 |
|
Número de diapositiva 26 |
26 |
|
Número de diapositiva 27 |
27 |
|
Synthetic Lethality: PARP Inhibitors |
28 |
|
High SLFN11 predicts improved outcome withTMZ/Veliparib |
29 |
|
ECOG –ACRIN 2511 Phase I–II R Study of Veliparib + EP vs Placebo + EP |
30 |
|
PARP inhibitors New Trials |
31 |
|
Número de diapositiva 32 |
32 |
|
Epigenetics, EZH2 and SCLC |
33 |
|
EZH2 inhibition can prevent acquired resistanceto 1L SCLC |
34 |
|
EZH2 inhibition can markedly improve 2L in chemoresistant SCLC |
35 |
|
Número de diapositiva 36 |
36 |
|
WEE1-targeted cell-cycle vulnerabilities |
37 |
|
Número de diapositiva 38 |
38 |
|
Other Inhibitors of other Targets |
39 |
|
Número de diapositiva 40 |
40 |
|
Número de diapositiva 41 |
41 |
|
Número de diapositiva 42 |
42 |
|
CHECKMATE 032 Non-R Cohort: OS |
43 |
|
CHECKMATE 032: 3-month PFS / OS |
44 |
|
CHECKMATE 032: Safety - pooled Cohorts |
45 |
|
CHECKMATE 032: TMB Analysis |
46 |
|
CHECKMATE 331: Ongoing Phase III Study |
47 |
|
KEYNOTE-028: SCLC Cohort |
48 |
|
Phase I study of Atezolizumab |
49 |
|
Ongoing IO studies in 2L+ |
50 |
|
Número de diapositiva 51 |
51 |
|
Número de diapositiva 52 |
52 |
|
Número de diapositiva 53 |
53 |
|
STIMULI: Nivolumab + Ipilimumab in LD |
54 |
|
CheckMate 451: Ongoing Phase 3 Study in ED-SCLC |
55 |
|
Phase II study of Maintenance Pembrolizumab in ES-SCLC in 1L |
56 |
|
Número de diapositiva 57 |
57 |
|
Alternative IO targets in SCLC |
58 |
|
Número de diapositiva 59 |
59 |
|
Biomarker Analysis in SCLC Immunotherapy |
60 |
|
Mercedes Clase S |
61 |
|
Número de diapositiva 62 |
62 |